ArticlePneumonia (Nathan Qld.)2026
Eosinopenia and prognosis in severe community-acquired pneumonia.
Article in Pneumonia (Nathan Qld.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundEosinopenia has been reported as a marker of severity in infections, but its prognostic value in patients with severe community-acquired pneumonia (CAP) admitted to the intensive care unit (ICU) is unclear.
methodsWe retrospectively analyzed 496 patients with severe CAP admitted to the ICU and stratified them according to the presence of eosinopenia on admission. We compared clinical characteristics, laboratory data, microbiological etiology, treatment, complications, and outcomes between groups. Independent factors associated with 30-day mortality were identified using multivariable Cox regression. Discriminative performance of eosinophil count, severity scores (CRB-65, CURB-65, PSI), and a modified CURB-65 incorporating eosinopenia (CURB-65Eos) were assessed using ROC curves.
resultsEosinopenia was present in 163/496 patients (33%). Age and most comorbidities were similar between groups. Compared with non-eosinopenic patients, eosinopenic patients had lower leukocyte, neutrophil, and lymphocyte counts and more frequent viral or polymicrobial infections. They more often required invasive mechanical ventilation (58% vs. 45%, p = 0.009) and developed pleural effusion (30% vs. 19%, p = 0.008). In-hospital and 30-day mortality were higher in the eosinopenia group (21% vs. 13%, p = 0.036; 20% vs. 12%, p = 0.022). In the predefined multivariable Cox model, eosinopenia was independently associated with increased 30-day mortality (HR 1.95; 95% CI 1.19 to 3.20; p = 0.008). Eosinophil counts alone showed poor discrimination for 30-day mortality (AUC 0.562), while established severity scores performed moderately. CURB-65Eos showed a numerical but nonsignificant improvement over CURB-65.
conclusionsEosinopenia is common in patients with severe CAP admitted to the ICU and is independently associated with increased 30-day mortality. It may serve as a simple and inexpensive biomarker for the early identification of high-risk patients and could complement established severity scores to support closer monitoring and earlier escalation of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.